Santaris Pharma begins human clinical testing of the world's first medicine targeted at a human microRNA
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection
30-May-2008
Most read news
Topics
Organizations
Santaris Pharma
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
BGU Scientists develop a Unique and Smart Delivery System of Medications to the Brain - Ben-Gurion University of the Negev Licenses Breakthrough Drug Delivery Platform for Central Nervous System Diseases to New York Biotech Company
Go to page
Poor sleep linked to PTSD after heart attack
Go to page
NicOx and TOPIGEN sign agreement for NCX 1020 in COPD and other respiratory diseases
Go to page
enViro-cell Umwelttechnik GmbH - Oberursel, Germany
Go to page
EuroGene GmbH - Leipzig, Germany
Go to page
Isotretinoin
Go to page
Cyplasin Biomedical Ltd., announces Licensing of Cyplasin technology
Go to page
BGU Kahn Center research group unravels genetic mutations for intestinal obstruction - Prof. Ohad Birk’s team identifies mutations in two different Bedouin tribes
Go to page
The Medical Research Council and GATC Biotech sign Sequencing Contract
Go to page
New regulator of eating behaviour identified - New potential approach to treating obesity
Go to page